The Added Value of Percentage of Free to Total Prostate-specific Antigen, PCA3, and a Kallikrein Panel to the ERSPC Risk Calculator for Prostate Cancer in Prescreened Men.

Moniek M Vedder; Esther W de Bekker-Grob; Hans Lilja; Andrew J Vickers; Geert J L H van Leenders; Ewout W Steyerberg; Monique J Roobol

doi:10.1016/j.eururo.2014.08.011

The Added Value of Percentage of Free to Total Prostate-specific Antigen, PCA3, and a Kallikrein Panel to the ERSPC Risk Calculator for Prostate Cancer in Prescreened Men.

Moniek M Vedder, Esther W de Bekker-Grob, Hans Lilja, Andrew J Vickers, Geert J L H van Leenders, Ewout W Steyerberg, Monique J Roobol

Research output: Contribution to journal › Article › peer-review

221 Downloads (Pure)

Abstract

Prostate-specific antigen (PSA) testing has limited accuracy for the early detection of prostate cancer (PCa).

Original language	English
Pages (from-to)	1109-1115
Journal	European Urology
Volume	66
Issue number	6
DOIs	https://doi.org/10.1016/j.eururo.2014.08.011
Publication status	Published - 2014

Subject classification (UKÄ)

Clinical Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.eururo.2014.08.011

1383288 Accepted author manuscript, 632 KBLicence: CC BY-NC-ND

http://www.ncbi.nlm.nih.gov/pubmed/25168616?dopt=Abstract

Cite this

Vedder, M. M., de Bekker-Grob, E. W., Lilja, H., Vickers, A. J., van Leenders, G. J. L. H., Steyerberg, E. W., & Roobol, M. J. (2014). The Added Value of Percentage of Free to Total Prostate-specific Antigen, PCA3, and a Kallikrein Panel to the ERSPC Risk Calculator for Prostate Cancer in Prescreened Men. European Urology, 66(6), 1109-1115. https://doi.org/10.1016/j.eururo.2014.08.011

@article{b242d10e35d8463a9e0d16144ae25cdd,

title = "The Added Value of Percentage of Free to Total Prostate-specific Antigen, PCA3, and a Kallikrein Panel to the ERSPC Risk Calculator for Prostate Cancer in Prescreened Men.",

abstract = "Prostate-specific antigen (PSA) testing has limited accuracy for the early detection of prostate cancer (PCa).",

author = "Vedder, {Moniek M} and {de Bekker-Grob}, {Esther W} and Hans Lilja and Vickers, {Andrew J} and {van Leenders}, {Geert J L H} and Steyerberg, {Ewout W} and Roobol, {Monique J}",

year = "2014",

doi = "10.1016/j.eururo.2014.08.011",

language = "English",

volume = "66",

pages = "1109--1115",

journal = "European Urology",

issn = "1873-7560",

publisher = "Elsevier",

number = "6",

}

Vedder, MM, de Bekker-Grob, EW, Lilja, H, Vickers, AJ, van Leenders, GJLH, Steyerberg, EW & Roobol, MJ 2014, 'The Added Value of Percentage of Free to Total Prostate-specific Antigen, PCA3, and a Kallikrein Panel to the ERSPC Risk Calculator for Prostate Cancer in Prescreened Men.', European Urology, vol. 66, no. 6, pp. 1109-1115. https://doi.org/10.1016/j.eururo.2014.08.011

TY - JOUR

T1 - The Added Value of Percentage of Free to Total Prostate-specific Antigen, PCA3, and a Kallikrein Panel to the ERSPC Risk Calculator for Prostate Cancer in Prescreened Men.

AU - Vedder, Moniek M

AU - de Bekker-Grob, Esther W

AU - Lilja, Hans

AU - Vickers, Andrew J

AU - van Leenders, Geert J L H

AU - Steyerberg, Ewout W

AU - Roobol, Monique J

PY - 2014

Y1 - 2014

N2 - Prostate-specific antigen (PSA) testing has limited accuracy for the early detection of prostate cancer (PCa).

AB - Prostate-specific antigen (PSA) testing has limited accuracy for the early detection of prostate cancer (PCa).

U2 - 10.1016/j.eururo.2014.08.011

DO - 10.1016/j.eururo.2014.08.011

M3 - Article

C2 - 25168616

SN - 1873-7560

VL - 66

SP - 1109

EP - 1115

JO - European Urology

JF - European Urology

IS - 6

ER -

The Added Value of Percentage of Free to Total Prostate-specific Antigen, PCA3, and a Kallikrein Panel to the ERSPC Risk Calculator for Prostate Cancer in Prescreened Men.

Abstract

Subject classification (UKÄ)

UN SDGs

Access to Document

Fingerprint

Cite this